Discover
filgotinib (GLPG0634) / GileadFilgotinib clinical trial estimate: Data from P3 Diversity1 trial (NCT02914561) for Crohn’s disease in Q2 2021 (Morgan Stanley) - Sep 18, 2019 - A subscription to Thomson ONE is required to gain full access to report 67932681; Page no: 4; REPORT TITLE: "Galapagos NV: Large differentiated pipeline headlined by Filgotinib, resume at OW”; AUTHOR: Harrison, Matthew, et al; DATE: 09/08/2019etrolizumab (RG7413) / RocheEtrolizumab: Data from P3 HIBISCUS 1 trial (NCT02163759) for ulcerative colitis in 2020 (Roche) - Sep 17, 2019 - Pharma Day 2019: Data from P3 HIBISCUS 2 trial (NCT02171429) for TNF naive ulcerative colitis in 2020 [Screenshot]etrolizumab (RG7413) / RocheEtrolizumab: Data from P3 HICKORY trial (NCT02100696) for ulcerative colitis in 2020 (Roche) - Sep 17, 2019 - Pharma Day 2019: Data from P3 BERGAMOT trial (NCT02394028) for moderate-to-severe Crohn's disease in 2021 [Screenshot]etrolizumab (RG7413) / RocheEtrolizumab: Data from P3 LAUREL trial (NCT02165215) for ulcerative colitis in 2020 (Roche) - Sep 17, 2019 - Pharma Day 2019: Data from P3 GARDENIA trial (NCT02136069) for moderate to severe ulcerative colitis in 2020P3 data[Screenshot]foralumab (TZLS-401) / Tiziana Life SciencesTiziana Life Sciences announces FDA approval to initiate phase I clinical trial with orally administered foralumab in healthy volunteers (Businesswire) - Sep 16, 2019 - "Tiziana Life Sciences plc...is pleased to announce...that the U.S. Food and Drug Administration (FDA) has allowed the initiation of a Phase I clinical trial in healthy volunteers using a novel oral enteric-coated capsule formulation of Foralumab....This is the first clinical trial in which Foralumab will be administered orally to healthy subjects."Tremfya (guselkumab) / J&JTremfya sales projection: $3B in 2024 (MainFirst Bank AG) - Sep 16, 2019 - A subscription to Thomson ONE is required to gain full access to report 67932139; Page no: 30; REPORT TITLE: "MainFirst AG- Initiating coverage: MainFirst: Morphosys AG (OPF / EUR 140): On the cusp of transformation supported by a fat wallet”; AUTHOR: Wieprecht, Marcus, et al; DATE: 09/08/2019Stelara (ustekinumab) / J&JStelara WW sales projection: $9B in 2024 (Cowen & Co) - Sep 23, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 479; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019Humira (adalimumab) / Eisai, AbbVieHumira patent expiry: January 2023 (Cowen & Co) - Sep 23, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 715; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019Rinvoq (upadacitinib) / AbbVieRinvoq: Newly added patents in Orange Book (Orange Book) - Sep 18, 2019 - Expiry of patents on December 1, 2030, January 15, 2031, October 17, 2036 [Screenshot]Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimSkyrizi sales projection: $250M in 2019, $850M in 2020 and $3B in 2024 (Cowen & Co) - Sep 23, 2019 - A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 491; REPORT TITLE: "Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019
